KEYNOTE-966 trial in progress: Pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer
AuthorsValle, Juan W
Kelley, R. K.
Finn, R. S.
Su, S. C.
Siegel, A. B.
AffiliationDivision of Cancer Sciences, University of Manchester/The Christie NHS Foundation Trust, Manchester, UK;
MetadataShow full item record
AbstractBackground: Biliary tract cancer (BTC), comprising intra- and extra-hepatic cholangiocarcinoma and gallbladder cancer, is a rare and aggressive malignancy. Most patients (pts) present with advanced or unresectable disease, for which the current standard of care is gemcitabine plus cisplatin. Median survival for these pts is only 12 months, highlighting the need for more effective therapies. Pembrolizumab is a PD-1inhibitor that has demonstrated modest antitumor activity as monotherapy in pts with previously treated BTC and has improved survival when used in combination with platinum-based chemotherapy in other cancer types.
CitationValle JW, Kelley RK, Furuse J, Edeline J, Finn RS, Ren Z, et al. 78TiP KEYNOTE-966 trial in progress: Pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer. Annals of Oncology. 2020;31:S270-S1.
JournalAnnals of Oncology
TypeMeetings and Proceedings